Chapter 12. Neurokinin Receptor Antagonists

Swain, Christopher J.; Hargreaves, Richard

doi:10.1016/s0065-7743(08)60451-0

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, RPR 100,893 has been reported to be ineffective at doses of up to 20 mg in Phase II clinical trials for the treatment of migraine [24]. While these results may be due to inadequate doses of the drug, or due to a lack of brain penetration, they raise questions about the effectiveness of NK1 receptor antagonists in the acute treatment of migraine [25]. Further clinical trials with more potent, brain-penetrant development candidates, as well as trials to test the efficacy of neurokinin antagonists in the prophylactic relief of migraine should resolve this issue.…”

Section: Rpr 100893mentioning

confidence: 99%

Neurokinin receptor antagonists

Elliott

Seward

1997

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

The competitive area of neurokinin (NK) receptor antagonists has recently seen the publication of early clinical results which provide strong support for their use in the treatment of pain, emesis and asthma. Preclinical models support their use in a number of additional disorders including anxiety, arthritis, migraine, cancer and schizophrenia. New indications, such as glaucoma and ocular hypotension, neuronal injury and stroke, cardiac disorders and topical applications have recently been claimed. Published patent applications from most of the major pharmaceutical companies claim a wide variety of structural classes as antagonists at all three neurokinin receptors. This review discusses the significance of new clinical data for ongoing drug discovery efforts, and patent claims for new indications and new structural classes for the period since the last review in early 1996.

show abstract

Section: Rpr 100893mentioning

confidence: 99%

Neurokinin receptor antagonists

Elliott

Seward

1997

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

show abstract

“…A number of recent publications have reviewed the potential therapeutic applications of neurokinin antagonists [1][2][3]. Based on preclinical models the indications suggested include: anxiety, migraine, emesis, asthma, inflammation, pain and schizophrenia.…”

Section: Introductionmentioning

confidence: 99%